Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNOVIIIUS: Efanesoctocog alfa prophylaxis for synovial hypertrophy in hemophilia A
jRCT2031250116Recruiting
- Sponsor
- Sanofi
- Start
- Mar 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of efanesoctocog alfa in hemophilia A, sponsored by Sanofi. Primary endpoint: Proportion of joints with improvement in HEAD-US synovitis domain score at Week 52. Started Mar 2026; status: recruiting.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2031250116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250116.